The U.S. Senate Finance Committee has voted to advance Robert F. Kennedy Jr.’s nomination for Secretary of Health and Human ...

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on BioNTech SE (BNTX – Research Report), with ...

We rate BioNTech SE a hold due to volatile performance, weak growth, and premium valuation amidst COVID-19 vaccine reliance. See more on BNTX stock here.

In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Shares of vaccine companies fell on Tuesday after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead ...

In the case of BioNTech, which is trading at $117.8 as of publishing time, $100 would buy you 0.85 shares of stock. If you're ... or sell a call option at a strike price above where shares are ...

The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and raised their price target for the stock from $90.00 to $137.00 in a research report on Friday ...

The firm issued a buy rating and a $172.00 price objective on the stock. A number of other analysts have also weighed in on the stock. Jefferies Financial Group upgraded shares of BioNTech from a ...

Investing.com -- Moderna (NASDAQ: NASDAQ: MRNA) stock declined 4.9% and BioNTech SE (NASDAQ: NASDAQ: BNTX) shares fell 1.5% ...